ArticleBlood cancer journal2021
Genetic complexity impacts the clinical outcome of follicular lymphoma patients.
Abstract readLetterComment
In one paragraph
Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.British journal of haematology · 2026Pooled it
- Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.International journal of molecular sciences · 2024Pooled it
- Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non-Hodgkin lymphomas.British journal of haematology · 2026Article
- Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.Cancers · 2025Review
- Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.Blood advances · 2023Article
Corrections and comments
- Comment on
Authors and funding
24 authors.
María García-ÁlvarezDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Sara Alonso-ÁlvarezDepartment of Hematology, Central University Hospital of Asturias (HUCA), Oviedo, Spain.
Isabel Prieto-CondeDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.ORCID 0000-0002-2510-8355
Cristina JiménezDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
M Eugenia SarasqueteDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.ORCID 0000-0001-7335-3657
M Carmen ChillónDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Alejandro MedinaDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.ORCID 0000-0001-5609-2969
Ana BalanzateguiDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Rebeca MaldonadoDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Alicia AntónDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Marta RodríguezDepartment of Pathology, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
Oscar BlancoDepartment of Pathology, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
Luis G DíazDepartment of Nuclear Medicine, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
Pilar TamayoDepartment of Nuclear Medicine, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
Pedro BlancoDepartment of Otorhinolaryngology, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
Carmen EstebanDepartment of General and Gastrointestinal Surgery, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
Verónica González-CalleDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Noemí PuigDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Norma GutiérrezDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Alejandro MartínDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Ramón García-SanzDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain. rgarcias@usal.es.ORCID 0000-0003-4120-2787
Marcos GonzálezDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
M Dolores CaballeroDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.
Miguel AlcocebaDepartment of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.ORCID 0000-0002-3819-4846
Funding
Consejería de Educación, Junta de Castilla y León (Consejería de Educación de la Junta de Castilla y León) CAS102P17Fundación Científica Asociación Española Contra el Cáncer (Scientific Foundation, Spanish Association Against Cancer) PROYE18020BEAMinistry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CD19/00030Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CIBERONC-CB16/12/00233Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CPII18/00028Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) FI19/00320Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI15/01390Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI18/00410Ministry of Economy and Competitiveness | Secretaría de Estado de Investigación, Desarrollo e Innovación (Secretary of State of Research, Development and Innovation) Innocampus; CEI-2010-1-0010
Abstract
PubMed holds no abstract for this paper.
Indexed as
Lymphoma, FollicularHumansTranslocation, Genetic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.